Quantum Leap Healthcare Collaborative™ is a 501C(3) charitable organization integrating high-impact clinical research with patient care to improve and save lives.

PORTFOLIO

Learn more about our projects

I-SPY Trials

Developing new cancer treatments faster and for less

Learn More

BreastCancerTrials.org

Personalized matching to breast cancer clinical trials

Learn More

CTMatch

Customizing trial matching to other diseases

Learn More

OneSource

Radically streamling collection and distribution of data

Learn More

I-SPY COVID

Focusing on the Problem with an Important New Solution

Learn More

Visit the I-SPY website for more information.

LEARN MORE

Latest News

June 6, 2022

UCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Read more

April 30, 2022

NEJM Authors’ Perspective cites FDA collaboration with OneSource in Real World Evidence discussion
Read more

April 29, 2022

OneSource Announced as a Grand Prize Winner in the 2022 Bio-IT World Innovative Practices Awards
Read more

June 6, 2022

UCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Read more

August 7, 2019

KEYTRUDA’s Success in TNBC Validates I-SPY 2 Adaptive Approach to Phase II Trials
Read more

February 15, 2019

Esserman among bioscience leaders profiled in SF Business Times
Read more
Portfolio
Quick Links
Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative™ is a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

© 2021 Quantum Leap Healthcare Collaborative.

This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.